insulin ce

39
INSULINS Rabia Tahir, Pharm.D. New York Harbor Healthcare System

Upload: jaymax13

Post on 07-May-2015

2.898 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Insulin Ce

INSULINSRabia Tahir, Pharm.D.

New York Harbor Healthcare System

Page 2: Insulin Ce

HISTORY of INSULIN Diabetes → 3500 years.

“Control” only by diet in past. Insulin discovered in 1921. Insulin used in 1st diabetic patient in 1922. 1st protein → chemically synthesized in 1963.

Page 3: Insulin Ce

INSULIN INDICATIONS Type I Diabetes

Absolute deficiency of insulin Type II Diabetes

Insulin resistance Relative insulin deficiency

Page 4: Insulin Ce

INSULIN INDICATIONS Insulin may be provided in two ways

Basal supplement with an intermediate to long-acting preparation to suppress hepatic glucose production and maintain near normoglycemia in the fasting state.

Premeal bolus dose of rapid-acting or short-acting insulin to cover the extra requirements after food is absorbed.

Page 5: Insulin Ce

TYPES of INSULIN 20 types available Which one should be used?

Individuals lifestyle Physicians preference Patients blood sugar level

Page 6: Insulin Ce

TYPES of INSULIN Which one should be used?

Source of insulin Obtained from pork pancreas or is made chemically identical to

human insulin by recombinant DNA technology. Beginning in January 2006, pork insulin for human use will no

longer be manufactured or marketed in the U.S.. 

How soon it starts working → onset. When it starts working the hardest → peak. How long it lasts in body → duration.

Page 7: Insulin Ce

TYPES of INSULIN Insulin onset, peak, and duration of effect must

match meal patterns and exercise schedules → achieve near normal blood glucose values throughout the day.

Four basic forms Rapid-acting insulins Short-acting insulins Intermediate-acting insulins Long-acting insulins

Page 8: Insulin Ce

RAPID-ACTING INSULINSType Onset (h) Peak (h) Duration (h)

Appearance

insulin lispro 15-30 min 1-2 3-4 Clear

HUMALOG

insulin aspart 15-30 min 1-2 3-5 Clear

NOVOLOG

insulin glulisine 15-30 min 1-2 3-4 Clear

APIDRA

NOVOLOG (insulin aspart) → formulary

Page 9: Insulin Ce

RAPID-ACTING INSULINS Administrative Options

HUMALOG (insulin lispro) Pen, U-100 vial, or 1.5 ml or 3 ml pen cartridge

NOVOLOG (insulin apart) Pen, U-100 vial, 3 ml pen cartridge

APIDRA (insulin glulisine) U-100 Vial

Page 10: Insulin Ce

RAPID-ACTING INSULINS Within 10 minutes of meal. Better efficacy in post prandial blood glucose. Minimizes delayed postmeal hypoglycemia. Normally used in regimens with intermediate

or long-acting insulin. Rapid-acting insulin can be mixed with NPH

and lente → the mixture should be injected within 15 minutes prior to a meal.

Page 11: Insulin Ce

SHORT-ACTING INSULINSType Onset (h) Peak (h) Duration (h)

Appearance

Regular 0.5-1.0 2-3 3-6 Clear

HUMULIN R

NOVOLIN R

NOVOLIN R → formulary

Page 12: Insulin Ce

SHORT-ACTING INSULINS Administrative Options

HUMULIN R U-100 vial, 10 ml vial or U-500, 20 ml vial

NOVOLIN R Insulin pen, U-100 vial, or 3 ml pen cartridge, and

Innolet

Page 13: Insulin Ce

SHORT-ACTING INSULINS Relatively slow onset of action when given SQ. Requires injection 30 minutes prior to meal to

achieve optimal post prandial glucose control and to prevent delayed postmeal hypoglycemia.

Eating within a few minutes after or before injecting is discouraged because it substantially reduces the ability of that insulin to prevent a rapid rise in blood glucose and may increase the risk of delayed hypoglycemia.

Page 14: Insulin Ce

INTERMEDIATE-ACTING INSULINType Onset (h) Peak (h) Duration (h)

Appearance

NPH 2-4 4-6 8-12 Cloudy

HUMULIN N

NOVOLIN N

Lente 3-4 6-12 12-18 Cloudy

HUMULIN L

Page 15: Insulin Ce

INTERMEDIATE-ACTING INSULIN Administrative Options

HUMULIN N U-100 vial, prefilled pen

NOVOLIN N U-100 vial, prefilled pen, and Innolet

HUMULIN L U-100 vial

Page 16: Insulin Ce

LONG-ACTING INSULINType Onset (h) Peak (h) Duration (h)

Appearance

Glargine 4-5 − 22-24 Clear

LANTUS

Page 17: Insulin Ce

LONG-ACTING INSULIN Administrative Options

LANTUS U-100 vial

Page 18: Insulin Ce

LONG-ACTING INSULIN LANTUS

‘peakless’’ analog → less nocturnal hypoglycemia than NPH when given at bedtime

Usually given once a day only

Page 19: Insulin Ce

PREMIXED INSULIN Fixed ratio insulins are dosed according to patient

needs 15 minutes before meals Premixed insulin analogs

HUMALOG Mix 75/25 (75% neutral protamine lispro, 25% lispro) U-100 vial, prefilled pen

NOVOLOG Mix 70/30 (70% aspart protamine suspension, 30% aspart) U-100 vial, prefilled pen, 3 ml pen cartridge

Page 20: Insulin Ce

PREMIXED INSULIN NPH-regular combinations

HUMULIN 70/30 Vial, prefilled pen

NOVOLIN 70/30 Vial, pen cartridge, Innolet

HUMULIN 50/50 Vial

Page 21: Insulin Ce
Page 22: Insulin Ce
Page 23: Insulin Ce

ADVERSE EFFECTS of INSULIN Hypoglycemia causes

Missing or delaying meals. Taking to much insulin. Exercising or working more than normal. An infection or illness (diarrhea and vomiting). Interactions with other drugs that lower blood

glucose → oral antidiabetic agents, salicylates, sulfa ab’s, certain antidepressants .

Consumption of alcoholic beverages.

Page 24: Insulin Ce

ADVERSE EFFECTS of INSULIN Hypoglycemia S&S

Mild to moderate - Sweating - Drowsiness- Dizziness - Sleep disturbances- Palpitation - Anxiety- Tremor - Blurred vision- Hunger - Slurred speech- Restlessness - Depressed mood- Tingling in hands, feet, lips, or tongue - Irritabilty- Lightheadedness - Abnormal behavior- Inability to concentrate - Unsteady movement- Headache - Personality changes

Page 25: Insulin Ce

ADVERSE EFFECTS of INSULIN Hypoglycemia S&S

Severe

- Disorientation- Unconsciousness - Seizures- Death

Page 26: Insulin Ce

ADVERSE EFFECTS of INSULIN Hypoglycemia Treatment (< 50mg/dl).

Mild to moderate Rule of 15 → 15g carbohydrate every 15 min until

BG is greater than 70mg/dl, then follow simple meal.

Severe or continuing Unable to take sugar by mouth or are unconscious

may need Dextrose 50% 50 ml infusion or Glucagon 1mg IM, SQ, or IV.

Page 27: Insulin Ce

ADVERSE EFFECTS of INSULIN Allergic reaction

Generalized reaction Uncommon but life threatening → itchy rash over

entire body, SOB, wheezing, confusion, low BP, tachycardia, sweating.

Local reaction At injection site and is common → itching, redness,

hardness, or swelling.

Page 28: Insulin Ce

ADVERSE EFFECTS of INSULIN Lipodystrophy

Change in fat below injection site Lipoatrophy Lipohypertrophy

Avoid injections in areas of skin that have theses reactions.

Page 29: Insulin Ce

MIXING INSULINS Formulations and particle size distribution

vary with insulin products. Mixing → physiochemical changes can occur

either immediately or over time. Serum insulin concentrations tend to reach a

single peak.

Page 30: Insulin Ce

MIXING INSULINS GUIDELINES Pt’s well controlled on mixed insulin regimen →

maintain their standard procedure. No other medication or diluents should be mixed

with insulin. Glargine (LANTUS) should not be mixed with any

insulin. Use of commercially available premixed insulins

may be used if insulin ratio is appropriate to Pt insulin requirement.

NPH and short-acting insulin when mixed can be used immediately or stored for future use.

Page 31: Insulin Ce

MIXING INSULINS GUIDELINES Rapid-acting insulin can be mixed with NPH, lente,

and ultralente. When rapid acting insulin is mixed with either an

intermediate or long-acting insulin → mixture should be injected within 15 min before meal.

Mixing of short-acting and lente insulins is not recommended except for Pt already adequately controlled on such mixture.

Phosphate-buffered insulins (NPH) should not be mixed lente insulins.

Page 32: Insulin Ce

INSULIN STORAGE Unopened vials, cartridges and pens.

If refrigerated use until expiration date (standard) If room temperature (below 30 º C) use within 28 days

Opened Vials within 28 days at room temperature or refrigerated Pen and pen cartridges within 28 days at room temperature (do

not refrigerate)

Do not use if insulin has been frozen or exposed to high temperatures (<2 º C or > 30 º C).

Excess agitation should be avoided.

Page 33: Insulin Ce

INSULIN ADMINISTRATION Check vial before use to inspect for changes

→ loss of potency. Vial and pens should be rolled in palms of

hands before drawing with needle → except with rapid and short acting insulin.

If mixing insulins → clear insulin should be drawn into syringe first.

Page 34: Insulin Ce

INSULIN DELIVERY DEVICES Insulin pens

Pens with cartridges → users turn a dial to select the desired dose of insulin → press a plunger on the end to deliver insulin.

Needle should be embedded within skin for 5 seconds after complete depression of plunger.

Air bubbles in pen reduces rate of insulin flow. Avoid leaving needle on pen between injections

and prime needle with 2 units of insulin.

Page 35: Insulin Ce

INSULIN DELIVERY DEVICES Jet injectors

Option for people who do not want to use needles.

Use high pressure air to send a fine spray of insulin through the skin as a fine stream.

Have no needles → advantage in patients unable to use syringes or with needle phobias.

More rapid absorption of short-acting insulins Costly and may traumatize skin.

Page 36: Insulin Ce

INJECTION SITE Subcutaneous tissue of upper arm. Anterior and lateral aspects of the thigh,

buttocks, and abdomen. IM not recommended. Rotation of injection site recommended.

Prevent lipohypertrophy and lipoatrophy. Rotating within one area is recommended.

Page 37: Insulin Ce

INJECTION SITE Variable absorption between sites.

Abdomen > arms >thighs > buttocks Exercise increases rate of absorption. Areas of lipohypertrophy have slower

absorption. IM > SC absorption.

Page 38: Insulin Ce

PREVENTING PAINFUL INJECTIONS Inject insulin at room temp. Make sure no air bubbles remain in syringe before

injection. Wait for topical alcohol to evaporate before

injection. Relax muscle at injection site at time of injection Penetrating skin quickly. Not changing direction of needle during insertion or

withdrawal.

Page 39: Insulin Ce

CONCLUSION Insulin type and species Injection technique Site of injection Individual Pt response differences

Onset Peak Duration